No earnings catalyst; watch for prula-cel data in mid-2026 as the next major price driver. The narrowed loss and maintained cash runway reduce near-term dilution risk.
Price Chart
Executive Summary
Adicet Bio reported Q1 2026 net loss of $20.2M ($1.88/share), narrowing from $28.2M ($4.96/share) YoY, primarily due to reduced R&D and G&A expenses. Cash position stands at $137.6M, sufficient into 2H 2027. No revenue or guidance changes; focus remains on upcoming prula-cel Phase 1 data in mid-2026 and ADI-212 regulatory filing in 3Q 2026.
Key Financial Metrics
Key Facts
- Net loss per share improved to $1.88 from $4.96 YoY
- Cash, cash equivalents and short-term investments: $137.6M as of March 31, 2026
- Cash runway extended into second half of 2027
- R&D expenses decreased to $17.5M from $22.8M YoY
- Prula-cel Phase 1 clinical update in LN and SLE expected mid-2026
- ADI-212 regulatory filing for mCRPC planned for 3Q 2026
Financial Impact
Net loss narrowed $8M YoY; no material financial impact beyond reduced burn rate.
Risk Factors
- Clinical trial failure or delay for prula-cel or ADI-212
- Dilution risk if additional capital needed after current cash runway
- Lack of revenue or near-term commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001720580-26-000036 |
| Document: acet-20260513.htm | 0001720580-26-000036 |
| Document: 0001720580-26-000036-index-headers.html | 0001720580-26-000036 |
| Document: 0001720580-26-000036-index.html | 0001720580-26-000036 |
| Document: 0001720580-26-000036.txt | 0001720580-26-000036 |
| 8-K Data (Synthetic) | 0001720580-26-000036 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | SC 13G | $4.03 | awaiting T+5 | — | $3.94 (−2.22%) |
Sep 28, 2026 28d ago | 8-K | $6.35 $6.47 | ▲ +1.89% | ▲ +0.69% | $3.94 (−37.95%) |
Sep 1, 2026 7w ago | 8-K | $9.26 $9.54 | ▲ +3.02% | ▲ +2.94% | $3.94 (−57.45%) |
May 20, 2026 22w ago | 10-K/A | $7.89 $9.31 | ▲ +18.00% | ▲ +16.15% | $3.94 (−50.06%) |
May 13, 2026 23w ago | 8-K | $8.41 $7.89 | ▼ −6.18% | ▼ −5.47% | $3.94 (−53.15%) |
Apr 8, 2026 28w ago | 144 | $6.86 $8.05 | ▲ +17.35% | ▲ +14.16% | $3.94 (−42.57%) |
Apr 7, 2026 28w ago | 144 | $6.55 $7.92 | ▲ +20.92% | ▲ +17.40% | $3.94 (−39.85%) |
Mar 24, 2026 30w ago | EFFECT | $6.69 $6.81 | ▲ +1.79% | ▲ +2.22% | $3.94 (−41.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers